PMC:7271924 / 3198-3382 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T59","span":{"begin":32,"end":36},"obj":"G_3;PG_10;PR:000003622"},{"id":"T60","span":{"begin":80,"end":88},"obj":"SP_7"},{"id":"T61","span":{"begin":117,"end":122},"obj":"SP_6;NCBITaxon:9606;PG_10"},{"id":"T62","span":{"begin":123,"end":127},"obj":"PG_10;PR:000003622"},{"id":"T67142","span":{"begin":32,"end":36},"obj":"G_3;PG_10;PR:000003622"},{"id":"T44915","span":{"begin":80,"end":88},"obj":"SP_7"},{"id":"T14445","span":{"begin":117,"end":122},"obj":"SP_6;NCBITaxon:9606;PG_10"},{"id":"T39251","span":{"begin":123,"end":127},"obj":"PG_10;PR:000003622"}],"text":" 2020 also investigated whether ACE2 blockade is a suitable option to attenuate COVID-19 (5). The use of recombinant human ACE2 (rhACE2) as ACE receptor competitor for binding has also"}

{"project":"LitCovid-PubTator","denotations":[{"id":"66","span":{"begin":32,"end":36},"obj":"Gene"},{"id":"67","span":{"begin":123,"end":127},"obj":"Gene"},{"id":"72","span":{"begin":117,"end":122},"obj":"Species"},{"id":"76","span":{"begin":129,"end":135},"obj":"Chemical"},{"id":"80","span":{"begin":80,"end":88},"obj":"Disease"}],"attributes":[{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"Gene:59272"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"Gene:59272"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"Tax:9606"},{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" 2020 also investigated whether ACE2 blockade is a suitable option to attenuate COVID-19 (5). The use of recombinant human ACE2 (rhACE2) as ACE receptor competitor for binding has also"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T12","span":{"begin":80,"end":88},"obj":"Disease"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" 2020 also investigated whether ACE2 blockade is a suitable option to attenuate COVID-19 (5). The use of recombinant human ACE2 (rhACE2) as ACE receptor competitor for binding has also"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T41","span":{"begin":49,"end":50},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T42","span":{"begin":117,"end":122},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T43","span":{"begin":176,"end":179},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":" 2020 also investigated whether ACE2 blockade is a suitable option to attenuate COVID-19 (5). The use of recombinant human ACE2 (rhACE2) as ACE receptor competitor for binding has also"}

{"project":"MyTest","denotations":[{"id":"32574271-32228252-34514557","span":{"begin":90,"end":91},"obj":"32228252"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":" 2020 also investigated whether ACE2 blockade is a suitable option to attenuate COVID-19 (5). The use of recombinant human ACE2 (rhACE2) as ACE receptor competitor for binding has also"}

{"project":"TEST0","denotations":[{"id":"32574271-113-118-2882149","span":{"begin":90,"end":91},"obj":"[\"32228252\"]"}],"text":" 2020 also investigated whether ACE2 blockade is a suitable option to attenuate COVID-19 (5). The use of recombinant human ACE2 (rhACE2) as ACE receptor competitor for binding has also"}

{"project":"2_test","denotations":[{"id":"32574271-32228252-34514557","span":{"begin":90,"end":91},"obj":"32228252"}],"text":" 2020 also investigated whether ACE2 blockade is a suitable option to attenuate COVID-19 (5). The use of recombinant human ACE2 (rhACE2) as ACE receptor competitor for binding has also"}